Lampert-Benignus E, Eichler-Reiss F, Meunier-Carius J, Keiling R
Biomed Pharmacother. 1985;39(2):87-93.
20 male patients were treated for various tumors, most of them by combination therapy program including Cis-diammino-dichloroplatinum, Methotrexate and Bleomycin, the mean total dose for this last drug being 225 mg in 3 months (75 mg-300 mg). Spirometric tests, carbon monoxide diffusing capacity (DLCO) and its components Dm (membrane diffusing capacity) and Vc (capillary blood volume) were performed before each course and at the end of the chemotherapy, to assess their value in detecting Bleomycin pulmonary toxicity. There was no statistically significant change in any ventilatory nor diffusional test among these 20 patients, carefully selected for the absence of cardiopulmonary history. There was a slight decrease of DLCO for 3 patients having received 300 mg of Bleomycin. The lack of cardiopulmonary history, the mean total dose under the toxic threshold, and perhaps the insufficient delay between the end of the treatment and the last control test, may explain this absence of variability of functional tests.
20名男性患者因各种肿瘤接受治疗，大多数患者采用包括顺二氨基二氯铂、甲氨蝶呤和博来霉素的联合治疗方案，最后一种药物的平均总剂量在3个月内为225毫克（75毫克至300毫克）。在每个疗程之前和化疗结束时进行肺量计测试、一氧化碳弥散能力（DLCO）及其组成部分Dm（膜弥散能力）和Vc（毛细血管血容量），以评估它们在检测博来霉素肺毒性方面的价值。在这20名因无心肺病史而精心挑选的患者中，任何通气或弥散测试均无统计学上的显著变化。接受300毫克博来霉素的3名患者的DLCO略有下降。无心肺病史、平均总剂量低于毒性阈值，以及可能在治疗结束与最后对照测试之间间隔时间不足，可能解释了功能测试缺乏变异性的原因。
